[1]
|
屠江锋, 潘文胜, 陈小君, 等. 胃癌早期筛查的研究进展[J]. 实用肿瘤杂志, 2016, 31(6): 560-564.
|
[2]
|
梁玉萍, 刘维花, 杨落落, 等. 早期胃癌的筛查[J]. 中华内科杂志, 2014, 53(4): 325-326.
|
[3]
|
Ishaq, S. and Nunn, L. (2015) Helicobacter pylori and Gastric Cancer: A State of the Art Review. Gastroenterology and Hepatology from Bed to Bench, 8, S6-S14.
|
[4]
|
Khatoon, J., Rai, R.P. and Prasad, K.N. (2016) Role of Helicobacter pylori in Gastric Cancer: Updates. World Journal of Gastrointestinal Oncology, 8, 147-158. https://doi.org/10.4251/wjgo.v8.i2.147
|
[5]
|
Chang, W.L., Yeh, Y.C. and Sheu, B.S. (2018) The Impacts of H. pylori Virulence Factors on the Development of Gastroduodenal Diseases. Journal of Biomedical Scifence, 25, 1-9. https://doi.org/10.1186/s12929-018-0466-9
|
[6]
|
Roesler, B.M., Rabelo-Gonçalves, E.M. and Zeitune, J.M. (2014) Virulence Factors of Helicobacter pylori: A Review. Clinical Medicine Insights. Gastroenterology, 7, 9-17. https://doi.org/10.4137/CGast.S13760
|
[7]
|
Baj, J., Brzozowska, K., Forma, A., Maani, A., Sitarz, E. and Portincasa, P. (2020) Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Tran-sition in Gastric Carcinogenesis. The International Journal of Molecular Sciences, 21, 2544. https://doi.org/10.3390/ijms21072544
|
[8]
|
Baj, J., Korona-Glowniak, I., Forma, A., Maani, A., Sitarz, E., Rahnama-Hezavah, M., Radzikowska, E. and Portincasa, P. (2020) Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer. Cells, 9, 1055. https://doi.org/10.3390/cells9041055
|
[9]
|
Hatakeyama, M. (2017) Structure and Function of Helicobacter pylori CagA, 104 China Continuing Medical Education, Vol. 10, No. 33 the First-Identified Bacterial Protein In-volved in Human Cancer. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 93, 196-219. https://doi.org/10.2183/pjab.93.013
|
[10]
|
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N. and Schlemper, R.J. (2001) Helicobacter pylori Infection and the Development of Gastric Cancer. The New England Journal of Medicine, 345, 784-789. https://doi.org/10.1056/NEJMoa001999
|
[11]
|
Zhang, L., Blot, W.J., You, W.C., et al. (1996) Helicobacter pylori Antibodies in Relation to Precancerous Gastric Lesions in a Highrisk Chinese Population. Cancer Epidemi-ology, Biomarkers & Prevention, 5, 627-630.
|
[12]
|
韩小磊, 何雁鸿, 马金丹, 等. 血清胃蛋白酶原在胃癌复发预测中的临床价值[J]. 胃肠病学和肝病学杂志, 2021, 30(12): 1339-1343.
|
[13]
|
杜梅英, 魏小斌, 钟文洲, 等. 胃泌素-17、胃蛋白酶原比值在早期胃癌筛查中应用价值分析[J]. 临床军医杂志, 2021, 49(7): 760-761, 764.
|
[14]
|
印睿, 葛建新, 黄晓丽, 等. 胃蛋白酶原、HLA-G诊断早期胃癌及癌前病变的临床意义[J]. 国际检验医学杂志, 2021, 42(24): 2977-2980.
|
[15]
|
朱春平, 赵建业, 申晓军, 等. 血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断价值的多中心临床研究[J]. 中华消化内镜杂志, 2017, 34(1): 19-23.
|
[16]
|
黄喜顺, 邓立新, 丘耀辉, 等. 血清PG、G-17联合CA72-4和13C UBT在早期胃癌的诊断价值[J]. 重庆医学, 2017, 46(10): 1346-1348.
|
[17]
|
陈志娟, 卢彩侠, 李艳艳, 等. 血清胃功能三项联合癌胚抗原和癌抗原72-4在胃癌早期筛查中的价值[J]. 中国肿瘤临床与康复, 2022, 29(2): 218-221.
|
[18]
|
唐承璐, 朱庆曦, 韩菊平, 等. 胃蛋白酶原及幽门螺杆菌抗体检测在早期胃癌筛查中的价值[J]. 湖南师范大学学报(医学版), 2019, 16(3): 99-102.
|
[19]
|
朱昱冰, 葛少华, 张连海, 等. 肿瘤标志物在胃癌患者中的诊断及预后价值[J]. 中华胃肠外科杂志, 2012, 15(2): 161-164.
|
[20]
|
徐明星, 李曼, 彭波, 等. 肿瘤标志物联检在胃癌早期诊断临床应用研究[J]. 中国实验诊断学, 2014, 18(6): 899-902.
|
[21]
|
付生弟, 谢辉. 肿瘤标志物CEA、CA19-9、CA72-4及CA242在胃癌诊断及预后判断中的应用价值[J]. 标记免疫分析与临床, 2016, 23(4): 428-430+450.
|
[22]
|
陈海燕. CA724、CEA、CA242、CA199肿瘤标志物联合检验在胃癌中的诊断价值[J]. 中国医药导报, 2012, 9(31): 97-98.
|
[23]
|
田福满, 韩波. 检测CA199、CA125、CA153及CEA在肿瘤诊断中的意义[J]. 临床和实验医学杂志, 2010, 9(7): 483-485.
|
[24]
|
Asao, T., Fukuda, T., Yazawa, S. and Nagamachi, Y. (1991) Carcinoembryonic Antigen Levels in Peritoneal Washings Can Predict Peritoneal Recurrence after Curative Resection of Gastric Cancer. Cancer, 68, 44-47.
https://doi.org/10.1002/1097-0142(19910701)68:1<44::AID-CNCR2820680109>3.0.CO;2-J
|
[25]
|
Zhang, Y.S., Xu, J., Luo, G.H., Wang, R.C., Zhu, J., Zhang, X.Y., Nilsson-Ehle, P. and Xu, N. (2006) Detection of Car-cinoembryonic Antigen mRNA in Peritoneal Washes from Gastric Cancer Patients and Its Clinical Significance. World Journal of Gastroenterology, 12, 1408-1411. https://doi.org/10.3748/wjg.v12.i9.1408
|
[26]
|
Ballehaninna, U.K. and Chamberlain, R.S. (2012) The Clinical Utility of Serum CA 19-9 in the Diagnosis, Prognosis and Management of Pancreatic Adenocarcinoma: An Evidence Based Appraisal. Journal of Gastrointestinal Oncology, 3, 105-119.
|
[27]
|
Feng, F., Tian, Y., Xu, G., Liu, Z., Liu, S., Zheng, G., Guo, M., Lian, X., Fan, D. and Zhang, H. (2017) Diagnostic and Prognostic Value of CEA, CA19-9, AFP and CA125 for Early Gastric Cancer. BMC Cancer, 17, Article No. 737.
https://doi.org/10.1186/s12885-017-3738-y
|
[28]
|
Kochi, M., Fujii, M., Kanamori, N., Kaiga, T., Kawakami, T., Aizaki, K., Kasahara, M., Mochizuki, F., Kasakura, Y. and Yamagata, M. (2000) Evaluation of Serum CEA and CA19-9 Levels as Prognostic Factors in Patients with Gastric Cancer. Gastric Cancer, 3, 177-186. https://doi.org/10.1007/PL00011715
|
[29]
|
Sisik, A., Kaya, M., Bas, G., Basak, F. and Alimoglu, O. (2013) CEA and CA 19-9 Are Still Valuable Markers for the Prognosis of Colorectal and Gastric Cancer Patients. Asian Pacific Journal of Cancer Prevention, 14, 4289-4294.
https://doi.org/10.7314/APJCP.2013.14.7.4289
|
[30]
|
Zhou, Y.-C., Zhao, H.-J. and Shen, L.-Z. (2015) Pre-operative Serum CEA and CA19-9 in Gastric Cancer—A Single Tertiary Hospital Study of 1,075 Cases. Asian Pacific Journal of Cancer Prevention, 16, 2685-2691.
https://doi.org/10.7314/APJCP.2015.16.7.2685
|
[31]
|
Chen, C., Chen, Q., Zhao, Q., Liu, M. and Guo, J. (2017) Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer. Annals of Clinical and Laboratory Science, 47, 260-263.
|
[32]
|
Sawayama, H., Iwatsuki, M., Kuroda, D., Toihata, T., Uchihara, T., Koga, Y., Yagi, T., Kiyozumi, Y., Eto, T., Hiyoshi, Y., et al. (2018) The Association of the Lymph Node Ratio and Serum Carbohydrate Antigen 19-9 with Early Recurrence after Curative Gastrectomy for Gastric Cancer. Surgery Today, 48, 994-1003.
https://doi.org/10.1007/s00595-018-1684-1
|
[33]
|
Hasbahceci, M., Malya, F., Kunduz, E., Guler, M., Unver, N. and Akcakaya, A. (2018) Use of Serum and Peritoneal CEA and CA19-9 in Prediction of Peritoneal Dissemination and Survival of Gastric Adenocarcinoma Patients: Are They Prognostic Factors? Annals of the Royal College of Surgeons of England, 100, 257-266.
https://doi.org/10.1308/rcsann.2018.0011
|
[34]
|
Sun, Z. and Zhang, N.-W. (2014) Clinical Evaluation of CEA, CA19-9, CA72-4 and CA125 in Gastric Cancer Patients with Neoadjuvant Chemotherapy. World Journal of Sur-gical Oncology, 12, 397.
https://doi.org/10.1186/1477-7819-12-397
|
[35]
|
Derks, S., Liao, X., Chiaravalli, A.M., et al. (2016) Abundant PD-L1 Expression in Epstein-Barr Virus-Infected Gastric Cancers. Oncotarget, 7, 32925- 32932. https://doi.org/10.18632/oncotarget.9076
|
[36]
|
Fukayama, M., Hayashi, Y., Iwasaki, Y., Chong, J., Ooba, T., Takizawa, T., Koike, M., Mizutani, S., Miyaki, M. and Hirai, K. (1994) Epstein-Barr Virus-Associated Gastric Carcinoma and Epstein-Barr Virus Infection of the Stomach. Laboratory Investigation, 71, 73-81.
|
[37]
|
Camargo, M.C., Murphy, G., Koriyama, C., Pfeiffer, R.M., Kim, W.H., Herrera-Goepfert, R., Corvalán, A.H., Carrascal, E., Abdirad, A., Anwar, M., et al. (2011) Determinants of Epstein-Barr Virus-Positive Gastric Cancer: An International Pooled Analysis. British Journal of Cancer, 105, 38-43. https://doi.org/10.1038/bjc.2011.215
|
[38]
|
Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemo-therapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697.
https://doi.org/10.1016/S0140-6736(10)61121-X
|
[39]
|
Van Cutsem, E., Bang, Y., et al. (2015) HER2 Screening Data from ToGA: Targeting HER2 in Gastric and Gastroesophageal Junction Cancer. Gastric Cancer, 18, 476-484. https://doi.org/10.1007/s10120-014-0402-y
|
[40]
|
Isgrò, M.A., Bottoni, P. and Scatena, R. (2015) Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Advances in Experimental Medicine and Biology, 867, 125-143. https://doi.org/10.1007/978-94-017-7215-0_9
|
[41]
|
Luo, H., et al. (2020) Clinical Significance of Serum Neuron-Specific Enolase in Gastric Adenocarcinoma. Medicine, 99, e19829. https://doi.org/10.1097/MD.0000000000019829
|
[42]
|
Wang, P., Piao, Y., Zhang, X., et al. (2013) The Con-centration of CYFRA 21-1, NSE and CEA in Cerebro-Spinal Fluid Can Be Useful Indicators for Diagnosis of Meningeal Carcinomatosis of Lung Cancer. Cancer Biomarkers, 13, 123-130. https://doi.org/10.3233/CBM-130338
|